Upfront surgery versus neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma in elderly patients: a multicenter cohort study
The optimal treatment strategy for elderly patients (aged ≥65 years) with operable locally advanced esophageal squamous cell carcinoma (ESCC) remains controversial. This study aimed to compare the survival outcomes of upfront surgery (US), neoadjuvant chemoimmunotherapy (nCIT), and neoadjuvant chemoradiotherapy (nC...